Authors : S S Jha, S S Jha
DOI : 10.18231/j.covid.2020.003
Volume : 1
Issue : 4
Year : 2020
Page No : 69-72
Severity of COVID-19 disease and heightened levels of prominent cytokines like IL-6, TNF-? and IFN-? do not bear uniform correlation. Evaluation of a specific cytokine panel at least confined to these three will be the key to precisely identify the differential cytokine pattern in each patient whether in ICU or out of ICU. Administration of selective immunosuppressive therapy becomes far more simpler after deciphering the particular cytokine level and targeting this cytokine.
Tocilizumab, anti IL-6 biologic usually is the targeted immunosuppressive therapy against the specific raised IL-6 titre for ICU severe COVID-19 patients. A combination of targeted therapeutic approach against the specific raised cytokines with possibly, an effective antiviral therapy should guide the management protocol.
Keywords: Cyotikines, IL-6, Tocilizumab, COVID-19, Cytokine storm, Cytokine panel, Immunosuppressive, Therapy.